

## Meeting Minutes

<b>Institution:</b>	Urology Center of Iowa Research		
<b>Meeting Date:</b>	September 29, 2025		
<b>Meeting Time</b>	12:00 PM Central Time		
<b>Meeting Type:</b>	Virtual Platform Teleconference (Remote) Open to the Public		
<b>Members in Attendance:</b>	<b>Member</b>	<b>Voting</b>	<b>Member Type</b>
	Bavaret, Tammy	Yes	Chair: Biosafety Expert/HGT Expert
	Campbell, Mark	Yes	Core Member: Biosafety Expert/HGT Expert
	Rastein, Daniel	Yes	Core Member: Biosafety Expert/HGT Expert
	Matos, Bethzayda	Yes	Local Unaffiliated Member
	Helgerson, Amy	Yes	Local Unaffiliated Member
	Hahn, Danielle	No	Site Contact
<b>Invited Members Not in Attendance:</b>	<b>Member</b>	<b>Voting</b>	<b>Member Type</b>
	None		
<b>Guests:</b>	None		
<b>Staff:</b>	Hemmelgarn, Marian		

**Call to Order:** The IBC Chair called the meeting to order at 11:59 AM. A quorum was present as defined in the Sabai IBC Charter.

**Conflicts of Interest:** The IBC Chair reminded all members present to identify any conflicts of interest (COI). No COI was declared by any voting member of the IBC for any of the items on the agenda.

**Public Comments:** No public comments were made prior to or at the meeting.

**Review of Prior Business:** None

**Previous Meeting Minutes:** Minutes from 9/9/25 were approved by the IBC with no changes.

## Meeting Minutes



### New Business:

<b>PI:</b>	Gallagher, Brian MD
<b>Sponsor:</b>	CG Oncology, Inc
<b>Protocol:</b>	CORE-008 A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
<b>Review Type:</b>	Annual Review
<b>NIH Guidelines Section:</b>	III-C-1

**Trial Summary:** CORE-008 is a multi-arm, open-label Phase II trial sponsored by CG Oncology, Inc. and designed to assess the safety and efficacy of cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer. The study agent cretostimogene grenadenorepvec consists of a recombinant, conditionally replicating oncolytic adenovirus. The investigational product (IP) is administered by intravesical instillation into the bladder.

**Biosafety Containment Level (BSL):** The study agent cretostimogene is based on a recombinant Risk Group 2 virus containing more than two-thirds of the native genome, requiring the use of BSL-2 containment under the NIH Guidelines.

### Risk Assessment and Discussion:

- The Committee reviewed the clinical trial Sponsor's study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
  - In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills, splashes, aerosols and needlesticks of the IP during preparation and/or administration procedures. During administration, failure or leaks of the catheter, instillation lines, or drainage bag could result in spill of the agent, or urine contaminated with the agent. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices (including Standard Precautions and sharps safety) and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).
  - The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
  - The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
  - The Site confirmed that staff members receive Bloodborne Pathogens training.

## Meeting Minutes

- Occupational Health Recommendations: The Sponsor notes that individuals who are at a potentially higher risk from working with or handling the study agent, such as pregnant or breastfeeding women and immunosuppressed or immunocompromised individuals, should not prepare, administer, or otherwise handle the study agent or materials contaminated with the study agent or provide direct care for treated participants presenting with any symptoms of illness attributed to cretostimogene for at least 1 week after treatment or until complete resolution of symptoms.
- The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.
- The Committee reviewed the Site's facility details, relevant study-specific procedures and practices, the Annual Review Report and other applicable information provided by the Site for the purposes of the IBC review.
  - The Site verified that the information provided by the Chair was accurate.
  - The Site confirmed the accuracy of the Annual Review Report.
  - The Committee discussed the Bloodborne Pathogen (BBP) training certificate provided by the Site noting that it reflects the initial issue date and the current expiration date. The Site confirmed the training is renewed annually.
  - The Committee discussed the location of the sink and plumbed eyewash noting they are located in an adjacent room to the exam rooms, not in the hall. The Facility Details form will be administratively updated to note this.
  - In response to a question from the Committee, the Site confirmed that the eyewashes are checked for expiration. The Site further discussed procedures for accessing the eyewash station in case of an eye exposure. The Committee had no further concerns.
  - The Site confirmed that the participant will remain in the administration room for the duration of the study agent retention period. The Chair reminded the Site that if the participant needs to be moved to a waiting room or other area during the retention period, the IBC will need to review and approve any new arrangements prior to their initiation. The Site had no concerns.

**Motion:** A motion of Full Approval for the study at BSL-2 was passed by unanimous vote. There were no votes against and no abstentions.

- Contingencies stated by the Committee: None
- Stipulations stated by the Committee: None

**Review of Incidents:** Nothing to report.

**IBC Training:** Nothing to report.

## Meeting Minutes



**Reminder of IBC Approval Requirements.**

**Adjournment:** The IBC Chair adjourned the meeting at 12:31 PM

**Post-Meeting Pre-Approval Note:** None